🏥 NHS Neighbourhood Health Hubs: How Community Care Will Work for People with Aspergillosis and Asthma

The NHS is changing how healthcare is delivered — with more care moving closer to home and fewer hospital visits.
A new model called Neighbourhood Health Services (or Neighbourhood Health Hubs) is being rolled out across England from late 2025, and it could make a real difference for people living with aspergillosis, asthma, bronchiectasis, and other long-term respiratory conditions.

🌍 Why care is moving into the community

The goal is to:

  • Bring care to where people live, not just in large hospitals

  • Reduce waiting times by shifting routine tests and reviews out of hospital clinics

  • Join up GPs, nurses, pharmacists, and hospital specialists into one local team

  • Focus on prevention, self-management, and early support

These reforms come from the government’s Healthcare on Your Doorstep announcement (September 2025), supported initially by £10 million across 43 pilot areas in England.

🧑‍⚕️ What a “Neighbourhood Health Hub” looks like

A one-stop local health centre bringing together:

  • GPs and practice nurses

  • Respiratory nurses, physiotherapists, and pharmacists

  • Mental-health and wellbeing workers

  • Dietitians, occupational therapists, and social-prescribing link staff

  • Voluntary and community organisations (e.g. NAC CARES, Asthma + Lung UK)

Some hubs will connect directly to Community Diagnostic Centres (CDCs) – local sites providing CT, MRI, X-ray, lung-function and blood tests through the NHS England diagnostics programme.
The aim is for one joined-up team to share your records and plan your care locally.

🩺 How hubs work with your GP and A&E

The new hubs are designed to fill the gap between GP surgeries and hospitals – giving extra support when you’re too unwell to manage alone but don’t need emergency care.

Home → GP Practice → Neighbourhood Health Hub → Hospital / A&E

🏠 Your GP surgery

You’ll stay registered with your usual GP. They remain in charge of your prescriptions, results, and overall care.
Your GP can now refer you to a Neighbourhood Health Hub for things that need a wider team – for example:

  • Antifungal monitoring or blood tests

  • Lung-function or CT scans

  • Flare-up review by respiratory nurses

  • Fatigue or wellbeing support

🧑‍⚕️ The Neighbourhood Health Hub

You might go here instead of hospital for:

  • Same-day assessment of an infection or flare-up

  • Bloods, ECGs, or scans ordered by your GP

  • Physiotherapy, airway-clearance or rehabilitation

  • Medication reviews with a pharmacist

  • Appointments with dietitians or mental-health staff

  • Practical help from link workers (see below)

🚨 A&E (Emergency Department)

Still essential for serious problems such as:

  • Sudden or severe breathlessness not relieved by treatment

  • Coughing up blood

  • Chest pain, fainting, or collapse

  • High fever with confusion
    If unsure, call NHS 111 or 999 in an emergency.

🔁 When to use which service

Situation Who decides Where you’ll be seen
Routine check-up or repeat prescription You / GP GP surgery
Specialist review or complex medication GP / consultant Neighbourhood Hub
Mild flare-up needing same-day care NHS 111 / GP Hub or GP
Emergency or life-threatening symptoms NHS 111 / 999 A&E / hospital
Diagnostic tests GP / hospital referral Community Diagnostic Centre

All sites will share your digital care record so results and updates reach your GP and hospital team automatically.

🧑‍🤝‍🧑 Link workers and care coordinators – local help through your GP

Every GP practice and neighbourhood team now has link workers (also called care coordinators or social prescribers).
They’re there to help you navigate healthcare and community support. They can:

  • Arrange or advise on transport for appointments

  • Help complete travel cost reimbursement or benefit forms

  • Connect you with volunteer driver schemes or local charities

  • Find exercise, wellbeing, or peer-support groups

  • Support with fatigue, isolation, or anxiety

Ask your GP reception or Neighbourhood Hub to refer you to the link worker, or request a call-back via the NHS App.

🚗 Transport and accessibility

🚐 NHS Patient Transport Service (PTS)

If you can’t use public transport for medical reasons (for example, oxygen use, mobility difficulties, or severe fatigue), you may qualify for free NHS transport.
Your GP, link worker, or hospital can book this for you through the regional PTS (for example, NWAS in the North West).

💷 Healthcare Travel Costs Scheme (HTCS)

If you’re on a low income or certain benefits, you can reclaim travel expenses under the HTCS.
Bring your appointment letter and proof of eligibility, or ask your link worker to help with the form.

🚙 Community & volunteer transport

Each Integrated Care System (ICS) works with local councils and charities such as Age UK, Mind, or Good Neighbour schemes to run community minibuses and volunteer driver services.
Ask your link worker or hub team for local options.

🅿️ Accessibility

All new and refurbished hubs must include:

  • Blue Badge parking and drop-off zones

  • Wheelchair-friendly entrances and toilets

  • Seating and oxygen-safe waiting areas

  • Negotiated free or reduced parking in shared sites

🧭 At a glance

Issue What’s planned What to do now
Public transport Sites chosen to be local, but not always central Check routes before your visit
NHS Patient Transport Still available for medical need Ask GP or link worker to book
Travel-cost reimbursement Continue via HTCS Keep proof of benefit
Community / volunteer drivers Expanding under ICB–VCS partnerships Request info via link worker
Disabled parking / drop-off Required at new sites Confirm when booking

🪶 A message from the aspergillosis community

For many people with lung disease, “local care” only works if it’s accessible care.
Groups such as NAC CARES, Asthma + Lung UK, and Healthwatch are urging NHS leaders to:

  • Design transport and parking into every new site

  • Ask about mobility and oxygen needs when booking

  • Fund local volunteer schemes

  • Provide dedicated link workers at every hub and GP practice

If you struggle to reach appointments, tell your clinic or Healthwatch — your feedback shapes how services develop.

🧾 Questions to ask before your first visit

  1. 🚗 Is there Blue Badge or patient parking on site?

  2. 🚌 What public-transport links serve the hub?

  3. 🚐 Can the clinic arrange NHS Patient Transport?

  4. 💷 Can I claim travel costs under the HTCS scheme?

  5. ♿ Is the building accessible for wheelchairs or oxygen users?

  6. 💨 Are there rest areas for people who get breathless?

  7. 🧑‍🤝‍🧑 Can my carer or partner attend with me?

  8. 👩‍💼 Is there a link worker who can help with transport or forms?

  9. 🕓 Are there quiet waiting spaces to reduce infection risk?

Having these answers before your appointment makes your visit smoother and safer.

💬 Final thought

“Neighbourhood care” isn’t about replacing your GP or A&E — it’s about bridging the gap.
The new hubs aim to bring together your GP, hospital specialists, and community teams in one local setting, providing earlier help, fewer hospital journeys, and care designed around your life, not your postcode.

🔎 Behind the Headlines: Is this an NHS Expansion or a Shift?

Many people wonder whether this is new investment or a reshuffle of existing NHS services.

🧱 What’s really happening

  • The Neighbourhood Health Service is not a new tier of the NHS, but a redesign of how GP, hospital, and community teams work together.

  • The focus is on moving care out of hospitals and into local clinics, using the same staff and budgets more effectively.

  • Hospitals will still handle emergencies and complex cases, but routine tests, reviews, and education will move into the hubs.

⚖️ Expansion or movement?

Area Expansion Reorganisation
Buildings Some new or refurbished hubs and diagnostics centres Many reusing existing GP or community facilities
Staffing Some new link workers, pharmacists, and AHPs Most existing NHS staff redeployed across neighbourhoods
Funding £10m pilot investment + diagnostic capital No major long-term new funding yet announced
Patient benefit Easier access, joined-up records May reduce hospital appointments rather than add capacity

💬 What this means

For patients, it should feel like an expansion — more care, closer to home —
but in reality it’s a shift of where and how NHS services are delivered, not a large-scale increase in total NHS resources.

⚠️ Risks and opportunities

Opportunities Risks
Easier local access Risk of hospital clinics closing before hubs fully staffed
Joined-up records Depends on IT integration
Focus on prevention May feel like hospital services are being reduced
Better continuity Needs clear accountability (GP vs hub)

🧩 Summary

The new neighbourhood model is a reorganisation within the NHS, not a separate expansion.
It aims to use existing staff, buildings, and budgets more efficiently — giving patients with chronic conditions like aspergillosis and asthma easier access to care and support in their own communities.

by GAtherton

🧩 NAC Aspergillosis Research Digest — Focus: Chronic Aspergillosis (October 2025: week 42)

🧬 Focus Review — Chronic Aspergillosis (October 2025)

Here are peer-reviewed papers on chronic aspergillosis published in the last month:

1. Improving Diagnostic Sensitivity Using Species-Specific IgG (Sep 2025)

  • This study investigated better blood tests to diagnose CPA by measuring IgG antibodies not just to Aspergillus fumigatus but also to other common Aspergillus species.

  • They found adding antibodies against non-fumigatus species identified more CPA cases that would have been missed by the standard A. fumigatus test alone.

  • The treatment results were similar regardless of which Aspergillus species was involved.

  • This means broader antibody testing improves diagnosis without changing expected outcomes.

  • Read full paper on PubMed

2. Prevalence and Impact of Bacterial Co-infections in CPA (April 2025)

  • This study looked at how often bacterial infections occur alongside CPA and their effect on patients.

  • About 21% of CPA patients had bacterial co-infections.

  • However, having a bacterial co-infection did not significantly change mortality rates compared to those without.

  • This highlights the need to assess for bacteria but suggests it may not worsen long-term outcomes.

  • Read full paper on PMC

3. Non-invasive Monitoring Using Serology and HRCT Imaging (June 2025)

  • Researchers combined blood antibody tests and high-resolution chest CT scans to identify active Aspergillus infections in chronic lung disease patients.

  • This method distinguished active infections from colonization without invasive procedures.

  • It supports using combined non-invasive tests to decide who needs further invasive diagnostics or antifungal treatment.

  • This approach helps avoid unnecessary treatments and invasive tests.

  • Read full paper on Frontiers

In short: these studies improve how doctors diagnose and monitor CPA — by expanding antibody testing beyond classic targets, recognizing the role but limited impact of bacterial co-infections, and using combined non-invasive testing strategies to guide management safely and effectively.

by GAtherton

🔍 Aspergillosis: Recent Highlights & Key Publications October 2025 (Week 41)

Revised ISHAM-ABPA working group guidelines (2024)

  • Scope & criteria: Codifies ABPA diagnosis around mandatory Aspergillus sensitisation (specific IgE or SPT) plus total IgE ≥ 500 IU/mL, with supporting features (Aspergillus-specific IgG/precipitins, eosinophilia, imaging with central bronchiectasis/mucus plugging). Distinguishes ABPA vs. ABPM (other fungi) and sets clinical states (acute, response, exacerbation, remission).

  • Treatment pathways: For acute ABPA, permits oral corticosteroids or itraconazole as first-line; combination is reasonable in severe disease or frequent relapsers. Provides steroid-sparing strategies (itraconazole/voriconazole/posaconazole) and practical taper schedules.

  • Biologics & monitoring: Positions omalizumab/mepolizumab/dupilumab for recurrent/exacerbation-prone ABPA. Recommends multidimensional response criteria (symptoms, exacerbations, lung function, IgE kinetics, radiology) rather than IgE alone.

  • Paper (Eur Respir J) · PubMed · OA summary (PMC).

BTS Clinical Statement on Aspergillus-Related Chronic Lung Disease (2025)

  • Who it’s for: UK-focused guidance to help respiratory teams manage CPA, aspergilloma, chronic airway disease with Aspergillus, and allergic phenotypes in secondary care.

  • CPA approach: Emphasises radiology over time (HRCT), microbiology/Aspergillus-IgG, and exclusion of mimics (NTM, malignancy). Advises long-term azoles (with TDM & LFTs), and when to consider surgery (haemoptysis/aspergilloma).

  • Service model: Encourages early referral/MDT (radiology, mycology, thoracic surgery, interventional radiology), signposts NAC pathways, and sets pragmatic follow-up intervals (clinical, radiology, serology).

  • BTS page · News item · (access via Thorax from BTS page).

Consensus guidelines for invasive aspergillosis (ECMM/ISHAM CAPA; 2021)

  • Definitions: Introduces proven/probable/possible CAPA using clinical + mycological evidence (BAL/TA culture or PCR, GM thresholds, imaging).

  • ICU nuance: Acknowledges non-neutropenic ICU patients (COVID/influenza) can develop IA with atypical imaging and lower fungal burdens; endorses combined biomarker strategies (BAL GM/PCR ± serum GM).

  • Therapy: Positions voriconazole/isavuconazole as first-line; L-AmB where resistance or intolerance suspected. Flags early initiation on high suspicion to improve outcomes.

  • Paper (Lancet Infect Dis) · PubMed · ECMM guideline hub.

Epidemiology & Clinical Cohorts

Marseille 2-year retrospective cohort — CPA & ABPA insights (2025)

  • Design: Single-centre retrospective study applying ESCMID CPA criteria and modified ISHAM ABPA criteria to consecutive referrals.

  • Findings: High rate of diagnostic overlap (allergy + chronic infection features). Delays to diagnosis common, especially where IgG negative/indeterminate but GM/BAL/PCR positive.

  • Implication: Supports multimodal testing (serology, GM/PCR, serial imaging) and repeat sampling in indeterminate cases; highlights value of centre-based MDT.

  • PubMed · (preprint/alt copies if needed: SSRN/other listing, ResearchGate record).

Invasive aspergillosis in ICU settings (2025 review)

  • Epidemiology: IA increasingly reported in severe viral pneumonias (COVID, influenza); mortality ~40–50% depending on definition and antifungal timing.

  • Diagnostics: BAL GM outperforms serum GM in non-neutropenic ICU; PCR adds sensitivity but needs pre-test probability framing to avoid over-calling colonisation.

  • Care points: Advocate protocolised screening (e.g., twice-weekly BAL GM/PCR in high-risk ventilated patients) and earlier empiric therapy when criteria met.

  • Open access review (Frontiers, 2025) · (alt listing: ResearchGate record).

Review: Invasive aspergillosis — scope & new species (2024)

  • Landscape: Expands on non-fumigatus Aspergillus species, cryptic species with distinct susceptibility patterns, and emerging hosts (advanced COPD, cirrhosis, ICU).

  • Resistance: Summarises azole resistance mechanisms (cyp51A variants, TR34/L98H, TR46/Y121F/T289A) and notes environmental selection via triazole fungicides.

  • Practice: Reinforces susceptibility testing and situational use of L-AmB or isavuconazole where resistance is likely.

  • Review (ScienceDirect).

Diagnostics: Biomarkers, Molecular, Imaging & Novel Methods

GM antigen & Aspergillus IgG negative “escape” cases

  • Problem: In suspected CPA/airway disease, Aspergillus-IgG can be false-negative early or in immunomodulated hosts.

  • Finding: High GM titres (especially BAL) can help “rescue” such cases, prompting treatment or further invasive sampling.

  • Clinical use: In IgG-negative but high-suspicion scenarios, pair BAL GM + PCR and repeat serology; avoid reliance on single negative IgG.

  • OA study (2025) · PubMed. (See also general GM/BDG performance review: Medicine 2024).

Molecular diagnosis, qPCR & NGS advances (2025 review)

  • Performance: qPCR improves sensitivity vs culture/microscopy; specificity hinges on contamination control and clinical context.

  • Best practice: Combine qPCR with GM/BDG in high-risk patients; consider cycle thresholds and duplicate positivity to support true infection.

  • NGS: Useful for broad pathogen screens or resistant/cryptic species; needs standardisation and careful interpretation.

  • OA review (Front Cell Infect Microbiol, 2025). British Thoracic Society

Microscopy, GM, PCR comparative pilot (2025)

  • Design: Head-to-head assay comparison across serum/BAL/sputum against a composite clinical reference.

  • Takeaway: No single test is definitive; dual-modality (e.g., BAL GM + PCR) yields best balance. Microscopy remains specific but insensitive.

  • Study (ScienceDirect). ERS Publications

Emerging spectroscopy / imaging techniques (TERS)

  • What it is: Tip-enhanced Raman spectroscopy mapping conidial wall components (melanin, polysaccharides, proteins) at nanoscale.

  • Why it matters: Potential to differentiate strains or track resistance-linked wall changes; currently preclinical, not diagnostic.

  • AIP Applied Physics Letters (2025) · arXiv preprint.

Therapeutics, Resistance & New Drugs

Olorofim (F901318) — Phase IIb results (2025)

  • Population: Refractory invasive mould disease (including azole-resistant Aspergillus), many salvage scenarios.

  • Efficacy: Global response ~29% (D42) and ~27% (D84); when counting stable disease, success rises to ~75% (D42) and ~63% (D84).

  • Safety: Transaminase elevations ~10%, mostly reversible with dose interruption/adjustment; no treatment-related deaths reported.

  • Use case: Salvage/compassionate therapy where standard options fail or resistance limits choices; monitor LFTs and DDIs.

  • PubMed · Lancet Infect Dis abstract. (Trial record: NCT03583164).

Review of olorofim in aspergillosis

  • MoA: Inhibits dihydroorotate dehydrogenase (DHODH), blocking de novo pyrimidine synthesis (novel class, no cross-resistance with azoles/echnocandins/AmB).

  • Signals: Case series in azole-resistant disease (incl. CGD) report clinical/radiologic remission; combination strategies under study.

  • Caveats: Access via trials/managed access; need phase III data and resistance surveillance under use pressure.

  • epocrates.com

Pipeline and alternative antifungals

  • Fosmanogepix (Gwt1 inhibitor): Oral/IV; activity against Candida/Aspergillus; CNS penetration promising; phase II positive signals.

  • Rezafungin (long-acting echinocandin): Weekly IV dosing enables OPAT; emerging real-world data in invasive disease and step-down.

  • Ibrexafungerp (tricohalose class/β-glucan): Oral; Aspergillus data limited (better for Candida), but combinations explored.

  • New azoles (isavuconazole real-world/TDM): Use where voriconazole intolerance or QT issues exist.

  • (See contemporary reviews; real-world rezafungin data below.)

Rezafungin (real-world, 2025) — OPAT-friendly weekly echinocandin; emerging safety/utility data.

Azole resistance & clinical implications

  • Drivers: Agricultural triazoles select environmental cyp51A mutations; patients can acquire primary resistant strains.

  • Practice changes: Where resistance prevalence is ≥10%, consider empiric L-AmB or isavuconazole until susceptibility known; always request AFST when feasible.

  • Nature Communications 2024 · Review PubMed.

Therapeutic drug monitoring & combination strategies

  • TDM: Essential for voriconazole/posaconazole (target troughs, avoid toxicity). Isavuconazole TDM less routine, but consider in extremes.

  • Combinations: Azole + echinocandin in refractory disease or high burden IA; AmB-based combos when resistance suspected. Evidence heterogeneous—use in expert-guided salvage.

  • (Covered within recent IA/therapy reviews above.)

Immunology, Host Responses & Biologics

Immunopathogenesis review (2023)

  • Pathways: Th2-skewed responses drive ABPA/SAFS (IgE/eosinophilia); defects in phagocyte function (neutropenia, CGD, high-dose steroids) predispose to invasive disease.

  • Mediators: Roles for IFN-γ, IL-5/IL-13, mucus hypersecretion, and airway remodelling; supports biologic targeting in allergic phenotypes.

  • OA review (Front Immunol 2023).

Biologics in ABPA / severe asthma

  • When to use: Relapsing ABPA, frequent steroid bursts, or steroid toxicity despite azole therapy.

  • Agents & effects: Omalizumab (anti-IgE) reduces exacerbations/steroid need; mepolizumab/benralizumab (anti-IL-5/IL-5R) tackle eosinophilia; dupilumab (anti-IL-4Rα) addresses Th2 axis and mucus/plugging.

  • Integration: Keep antifungal therapy for fungal burden; use biologics to control inflammation/exacerbations and spare steroids; monitor IgE dynamics and radiology.

  • ISHAM ABPA paper · PubMed.

by GAtherton

Living Healthier with Aspergillosis: Small Steps That Can Make Life Easier

Living with aspergillosis, whether it is allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), or another form, often means dealing with fatigue, coughing, breathlessness, repeated infections, and the side effects of treatment. Medicines such as antifungals and biologics are central to care, but everyday choices around food, activity, rest, and stress can also make a real difference.

This isn’t about strict rules or being told what you “should” do. It’s about finding small, realistic steps that help you feel stronger and more in control of daily life.

Why healthy habits can feel hard

Many people know what’s “healthy” but still find it difficult to change routines. That’s normal. Habits stick for lots of reasons:

  • Familiar routines feel safe, even if they’re unhelpful.

  • Stress, tiredness, or sadness can make comfort eating or smoking feel like a quick fix.

  • Friends, family, and culture shape our patterns.

  • Healthy food or exercise can seem expensive or time-consuming.

  • Mood and motivation play a huge part — especially if you’re already coping with illness.

Understanding why change is tough is the first step. You’re not failing — you’re human.

The potential benefits of living a little healthier

  • Easier breathing → avoiding smoke and doing gentle activity can help your lungs cope better.

  • Fewer flare-ups and infections → nourishing food, better sleep, and stress control support your immune system.

  • More energy → balanced eating and regular movement often boost stamina and reduce fatigue.

  • Treatments working better → some habits (like smoking or alcohol) interfere with antifungals; avoiding these can make medicines more effective.

  • Improved mood → routines such as exercise, cooking, or group activities can ease anxiety and give a sense of connection.

Diet and weight: it’s about health, not the scales

When weight feels like the focus

Many people are told to lose weight, but strict weight-loss diets rarely succeed in the long term. They can leave people frustrated or feeling worse. For aspergillosis, the aim is not chasing numbers on the scales — it’s about supporting your body so you can feel and function better.

Why diets often fail:

  • Cutting things out makes us crave them more.

  • The body resists weight loss by slowing metabolism.

  • Diets feel temporary, not sustainable.

  • One slip can feel like failure.

  • Stress and emotions drive food choices as much as hunger.

Breaking that cycle

Some people find it more helpful to:

  • Focus on health gains (more stamina, fewer infections, better mood) instead of weight loss.

  • Make small, sustainable swaps they can keep for years.

  • Add nourishing foods (protein, fruit, vegetables) instead of strict restriction.

  • Notice and celebrate everyday wins — walking further, coughing less, sleeping better.

When the struggle is keeping weight on

Not everyone has weight to lose. For some, infections, inflammation, and the effort of breathing can burn through calories, making it hard to maintain weight. In that case, the goal shifts to adding in extra energy and protein:

  • Eat smaller portions more often.

  • Fortify food with milk powder, cheese, cream, nut butters, or olive oil.

  • Keep calorie-rich snacks handy (flapjacks, trail mix, smoothies).

  • Try nutritional drinks (Fortisip, Ensure, or homemade shakes).

  • Ask your team for dietitian support if weight keeps dropping.

When to seek specialist help

General lifestyle tips are a useful starting point, but some people face severe or complex dietary problems. These can include:

  • Ongoing or severe weight loss / malnutrition

  • Difficulty swallowing or digesting food

  • Drug–food interactions (e.g. antifungals with certain juices or stomach acid medicines)

  • Other health conditions (diabetes, coeliac disease, kidney problems)

  • Persistent nausea, diarrhoea, or appetite loss from treatment

If this sounds familiar, the best step is to ask for a referral to a registered dietitian. A dietitian can:

  • Create a personalised nutrition plan to match your energy and protein needs

  • Suggest practical adjustments if eating is difficult

  • Ensure your plan is safe alongside antifungal or steroid treatment

  • Provide access to prescription nutritional supplements if needed

  • Monitor progress and adjust over time

What works for one patient may not be safe for another — professional advice ensures the plan is right for you.

Gut health and the microbiome

There’s growing interest in the link between the gut and the lungs — sometimes called the gut–lung axis. A healthy gut microbiome (the community of bacteria and other microbes in the digestive system) can support overall immunity and help regulate inflammation, which matters in conditions like ABPA and CPA.

  • Fibre feeds healthy gut bacteria → fruits, vegetables, oats, beans, and nuts help your gut produce anti-inflammatory compounds.

  • Probiotics (live “friendly bacteria” in yoghurts or supplements) may help some people, especially after antibiotics, but the evidence in aspergillosis is still limited.

  • Balance is key → too much fibre all at once can cause bloating; start gradually and pair fibre with calorie-rich foods if you struggle with weight.

  • Hydration matters → fibre works best when you’re drinking enough fluids.

  • Check before supplements → always discuss probiotic products with your team, especially if you are immunocompromised.

Small steps — like adding an extra piece of fruit or trying a yoghurt with live cultures — can gently support gut balance without overloading.

Starting small (and letting it grow)

Big lifestyle overhauls are rarely realistic. A more helpful approach is:

  • Pick one tiny change — a 10-minute walk, one less sugary drink, or a piece of fruit with breakfast.

  • Celebrate the success — each small step builds confidence and momentum.

  • Notice the ripple effect — walking more may improve sleep; better sleep may give more energy for cooking.

  • Climb the ladder slowly — the first step is hardest, but it makes the next ones easier.

Finding support

  • Share your goals with your medical team — they can suggest safe exercise, eating tips, or referrals.

  • Join pulmonary rehab, exercise groups, or online communities — peer encouragement makes a big difference.

  • Explore local schemes — social prescribing, community cooking, or walking groups can be free and welcoming.

  • Remember: mental health matters too. If low mood or anxiety makes change feel impossible, speaking with a GP or counsellor can help unlock progress.

The bottom line

Treatments like itraconazole and benralizumab are essential in controlling aspergillosis, but they work best when supported by healthy routines.

Living healthier means different things for different people:

  • For some, it’s cutting down alcohol or moving a little more.

  • For others, it’s eating enough to keep strength up.

  • For everyone, it’s about supporting your lungs, your body, your gut, and your wellbeing, not chasing numbers or perfection.

Even small, steady steps — chosen by you, at your pace — can add up to meaningful improvements and make daily life with aspergillosis a little easier.

by GAtherton

Integrated Care Boards (ICBs): What They Are and How Patients Can Contact Them

What is an ICB?

  • An Integrated Care Board (ICB) is the NHS organisation that replaced Clinical Commissioning Groups (CCGs) in July 2022.

  • Each ICB plans and funds NHS services across a large region (1–3 million people).

  • England has 42 ICBs, covering the whole country (see full list plus contact details here).

  • They hold the NHS budget locally, decide which services are provided, and work with councils and community organisations.

  • Scotland, Wales and Northern Ireland have a different system

Why might a patient need to contact an ICB?

Patients don’t normally deal with ICBs day-to-day (you’ll usually go to your GP, hospital, or local Patient Advice and Liaison Service). But there are situations where you may want or need to reach out:

  • Feedback or complaints about NHS services that can’t be resolved at GP or hospital level.

  • Service changes – ICBs must consult the public when they change how services are delivered (e.g. reorganising clinics, closing or merging hospital departments).

  • Patient voice – ICBs have teams dedicated to patient and public involvement. You can join forums, respond to surveys, or attend public meetings.

  • Access to care – if you are struggling to access a specialist service or want to know what’s available in your area, ICBs can advise.

  • Equality of access – raising concerns if a particular group or community is being left behind.

How can a patient contact an ICB?

  • Patient Experience / Engagement Teams: Every ICB has an email and phone number for patients. Look for “Get Involved” or “Contact Us” on their website.

  • PALS escalation: If PALS (Patient Advice and Liaison Service) can’t resolve your concern, they can refer it up to the ICB.

  • Public board meetings: ICBs must hold regular meetings in public where patients can submit questions.

  • Healthwatch: Your local Healthwatch can raise issues directly with the ICB on your behalf.

✅ In summary:
Patients usually don’t need to contact an ICB for routine issues, but if you want your voice heard about service changes, access problems, or unresolved complaints, the ICB is the organisation responsible for commissioning services in your area.

by GAtherton

Comparing Health Systems: NHS vs Insurance-Based Models

Healthcare looks very different depending on where you live, and it can be informative to look at the pros and cons of each system.
The UK’s NHS model is often contrasted with insurance-based systems such as those in the US and Germany. All aim to look after patients, but they differ in cost, access, caution with new medicines, and their contribution to research.

1. Funding and Access

NHS (UK)

  • Publicly funded through taxation.

  • Care is free at the point of use.

  • Limited co-payments (e.g. prescriptions in England, but free in Scotland/Wales/NI).

Insurance-Based (US, Germany)

  • US: Mix of private insurance, employer-based plans, and public programs (Medicare/Medicaid). Patients often pay premiums, deductibles, and co-pays.

  • Germany: Statutory health insurance (public) plus private options. Patients contribute through payroll and some co-payments.

✅ Equity difference: The NHS ensures universal coverage. Insurance systems can create gaps — in the US, uninsured or underinsured patients face very high bills.

2. Cost

  • United States: ~16–17% of GDP, >$12,000 per person per year.

  • Germany: ~11–12% of GDP, ~$6,000–7,000 per person.

  • United Kingdom: ~10% of GDP, ~$4,500 per person.

✅ Insurance-based systems are much more expensive overall. The NHS achieves lower cost per head but sometimes with tighter rationing.

3. Approach to New Medicines

NHS (cautious, evidence-driven)

  • Drugs are appraised by NICE (National Institute for Health and Care Excellence).

  • Only those proven clinically effective and cost-effective are routinely available.

  • Access can be slower, but ensures sustainability and safety.

Insurance-Based (faster, autonomy-driven)

  • Once a drug is licensed (FDA in US, EMA in EU), doctors may prescribe it, often off-label.

  • Patients may be offered newer or experimental options earlier.

  • Shared decision-making: “This might help, here are the risks, do you want to try it?”

✅ Trade-off: Insurance systems offer earlier access, but higher risk of side effects, wasted cost, and overuse. NHS offers more consistency but less flexibility.

4. Risks of Wide Access

Allowing rapid use of new drugs can lead to:

  • Harm to patients:

    • US:

      • Vioxx (rofecoxib) was widely prescribed for arthritis before long-term data was available → later linked to tens of thousands of excess heart attacks and strokes.

      • Opioid overprescribing (encouraged by drug companies, reimbursed by insurers) fuelled a public health crisis, with millions addicted and >500,000 deaths.

    • Germany: Wider acceptance of MCAS and other “working diagnoses” sometimes leads to long-term medication without solid evidence, exposing patients to risks without clear benefit.

  • Harm from NHS caution:

    • UK:

      • Cystic fibrosis drug Orkambi: available in the US and Germany years earlier, but withheld in the UK until 2019 due to cost-effectiveness debate → children and young adults missed out on years of treatment.

      • Cancer immunotherapies: delays in NICE approval have meant some patients only got access through special trials or not at all, potentially shortening survival.

5. Doctor–Patient Conversations

  • Insurance systems: “You may have this condition, and drug X or Y might help. It’s your choice.”

  • NHS: “We know you have this condition. X is proven and available. Y is unproven or not funded, so we cannot recommend it.”

✅ Insurance systems emphasise autonomy and options. The NHS emphasises evidence and fairness.

6. UK Private Healthcare vs US Healthcare

It’s tempting to think the UK private sector is equivalent to the US system, but they are very different.

UK Private Care

  • Covers about 10–12% of the population, mainly for elective surgery, scans, and faster consultant appointments.

  • Usually funded by employer insurance or self-pay.

  • Still relies on the NHS for emergencies and complex care.

  • New medicines still follow NICE approval — patients don’t usually get earlier access to unapproved drugs.

US Healthcare

  • Insurance-based and the default system, covering almost everyone.

  • Patients pay premiums, deductibles, and co-pays — bills can be catastrophic without good cover.

  • Emergencies are treated but still billed.

  • Patients may access new drugs and technology earlier, but often at very high cost.

✅ Bottom line: UK private care is an add-on to the NHS, giving faster access but within the same medical framework. The US system is entirely insurance-driven, with no NHS-style universal fallback.

7. Research Strengths

  • Insurance-based systems (esp. US):

    • Huge budgets (NIH + pharma).

    • Early adoption → more real-world data.

    • Specialist centres attract rare-disease patients.

  • NHS system:

    • Unified data across the whole population.

    • Ability to run massive pragmatic trials cheaply (e.g. RECOVERY during COVID: identified dexamethasone as life-saving within weeks).

    • More representative recruitment because care is universal.

✅ Together they complement each other:

  • New drugs are often developed and trialled first in the US/Germany.

  • Large-scale validation and population-level studies often happen in the UK.

8. Which System Is “Better”?

It depends what you value most:

  • Insurance-based systems:

    • More expensive

    • Faster access to innovation

    • More choice and autonomy

    • Higher risk of harm and inequality

  • NHS:

    • Less expensive

    • Slower, more cautious

    • Equitable and universal

    • Sometimes frustratingly restrictive

✅ Bottom Line

No system is perfect.

  • Insurance-based systems favour speed, choice, and innovation — but have caused harm through early adoption of unsafe drugs, opioid overuse, and inequitable access.

  • The NHS favours equity, safety, and sustainability — but has harmed patients by delaying access to life-saving treatments while cost-effectiveness was debated.

  • UK private healthcare is not a parallel US-style system: it is simply a faster lane within the NHS framework, not an alternative to universal coverage.

The reality is that both types of systems need each other: innovations often emerge in the US/Germany, while the NHS provides the gold standard for large-scale testing and equitable delivery.

by GAtherton

Mannose-Binding Lectin (MBL) Deficiency and Aspergillosis

What is MBL?

Mannose-binding lectin (MBL) is a natural protein made by the immune system. Its job is to help the body recognise and fight off germs, including fungi like Aspergillus. It’s part of the “innate” immune system – the first line of defence you’re born with.

How common is MBL deficiency?

MBL deficiency is surprisingly common.

  • Around 5–10% of people have very low or absent levels.

  • If you include milder reductions, as many as 20–30% of people carry genetic changes that lower MBL activity.

For most, this causes no problems because the immune system has other pathways to fall back on. People often never know they have it.

Why do MBL levels vary?

  • Genetics: The MBL2 gene comes in different versions, some producing plenty of MBL and others producing little or none.

  • Inheritance: The combination of gene copies from each parent determines your level.

  • Normal diversity: Low levels are common and often harmless, showing the immune system has strong backup pathways.

Are some people born more vulnerable to infection?

Yes – but it depends on the situation.

  • Children with very low MBL may get more ear, chest, or sinus infections while their immune systems are developing.

  • In adults, MBL deficiency usually only matters if there are other risks, such as chronic lung disease, immune suppression, or another immune problem.

  • Many people with low MBL live their whole lives without extra infections.

MBL deficiency and aspergillosis

On its own, MBL deficiency rarely causes illness. But in people who already have other risks – such as lung disease (COPD, asthma, bronchiectasis, or TB damage) or a weakened immune system – it may make infections more likely.

Research suggests MBL deficiency can be linked to:

  • Chronic pulmonary aspergillosis (CPA)

  • Allergic bronchopulmonary aspergillosis (ABPA)

  • Invasive aspergillosis in people with suppressed immunity

In these cases, MBL deficiency is not the single cause of aspergillosis, but it may be one of several factors that increase vulnerability.

Can MBL deficiency be treated?

At present, there is no routine treatment to replace MBL itself. Research has explored giving purified MBL, but it hasn’t become a standard therapy – largely because deficiency is so common and most people remain healthy without intervention.

Instead, management focuses on:

  • Treating infections promptly with antibiotics or antifungals

  • Sometimes using preventive (prophylactic) antibiotics or antifungals in people with frequent or severe infections

  • Using immunoglobulin replacement therapy if there are additional immune problems

  • Supporting lung health and reducing risks with vaccinations, good self-care, and specialist monitoring

Why measure MBL if it can’t be treated directly?

Even without a direct treatment, measuring MBL can still be useful:

  1. Helps explain recurrent infections – finding a low MBL level can give part of the reason why someone is more prone to infections.

  2. Part of a bigger immune work-up – it’s often checked alongside other immune tests, and the overall pattern may guide treatment decisions.

  3. Risk awareness – knowing about low MBL can make doctors more proactive with antibiotics, antifungals, or vaccinations, and encourage earlier treatment at the first sign of infection.

  4. Research value – helps specialists understand why some people develop aspergillosis while others don’t.

Why hasn’t evolution eliminated low MBL?

  • Common worldwide: 5–10% of people have very little MBL, and up to 30% have reduced levels. If this were a major disadvantage, numbers would be lower.

  • Other immune pathways compensate: The body has strong backup systems, so many people stay healthy even with low MBL.

  • Possible advantage: In some infections, high MBL may drive too much inflammation. Lower MBL might have protected against diseases like leprosy or TB.

  • Changing disease patterns: In the past, people rarely lived long enough for chronic lung disease to show the effects of low MBL. Today, with longer lives and modern medicine, its role is more visible.

👉 In short: low MBL has not been “selected out” by evolution because it usually isn’t harmful on its own, and in some situations it may even have been protective.

What this means for patients

  • Having MBL deficiency is quite common and usually harmless.

  • It may become more relevant if you also have underlying lung disease or are on treatments that suppress the immune system.

  • If MBL deficiency is suspected, doctors may check for it as part of a wider immune work-up.

  • The key point: treatment is aimed at managing infections and lung health, not the MBL level itself.

👉 In short: MBL deficiency is common in the general population. Most people never notice it, but for some with lung disease or weakened immunity, it may add to the risk of aspergillosis. While there’s no direct treatment for the deficiency, testing can help explain recurrent infections, guide wider immune checks, and shape preventive care.

by GAtherton

Autumn 2025 COVID-19 Booster – What Aspergillosis Patients Need to Know

The UK Health Security Agency (UKHSA) has updated who will be offered the COVID-19 booster this autumn. The programme is now more limited than in 2024, so it’s important to know if you qualify.

Who will be offered the booster?

You can get a free COVID-19 booster this autumn if you are:

  • Aged 75 or over

  • Living in a care home for older adults

  • Aged 6 months or older and immunosuppressed

This is a change from 2024, when everyone aged 65+ and many other clinical risk groups were included.

What “immunosuppressed” means

Many people with aspergillosis fall into this category. You may be considered immunosuppressed if you are:

  • Taking systemic steroids for more than a month

  • Receiving biologic therapy or other immunomodulatory medication

  • Living with a condition that affects your immune system

  • Having had chemotherapy, radiotherapy, or a transplant

If you’re unsure whether this applies to you, check with your GP or hospital specialist.

Timing of the booster

  • Boosters are usually offered at least 6 months after your last dose, including the spring booster.

  • Even if you’ve never had a COVID-19 vaccine before, you can still get one this autumn if you are in one of the eligible groups.

Why this matters for aspergillosis patients

People with aspergillosis often have weaker lungs and higher risks from infections. If your immune system is also suppressed by medication or illness, COVID-19 can be more severe. The booster offers added protection during the winter months.

💙 Key advice:

  • If you are immunosuppressed or over 75, you should be offered the vaccine.

  • If you think you qualify but haven’t received an invitation, speak to your GP or specialist.

  • Don’t delay — protecting yourself against COVID-19 is especially important when living with aspergillosis.

📌 Full details from UKHSA: Who’s eligible for the 2025 COVID-19 vaccine or autumn booster

by GAtherton

Drug Safety in the UK: What Aspergillosis Patients Need to Know

Living with aspergillosis often means taking powerful medicines for a long time — antifungals, steroids, antibiotics, or even biologics. These treatments can be life-saving, but they can also cause side effects, especially when used together. It’s natural to wonder: How do we know these drugs are safe? What happens if something goes wrong?

This article explains how drug safety is managed in the UK, what happens when rare problems occur, and what resources patients can use to protect themselves.

How Medicine Safety Works

Before a drug is approved:
Every new medicine goes through several phases of clinical trials. These trials are not just about proving that the drug works (efficacy) — they are also about proving it is safe enough to use in people. Researchers record every possible side effect, monitor blood tests, and look for safety signals as well as improvements in the illness.

However, trials have limits. They usually include only a few thousand participants, so they can reliably detect common side effects but not very rare ones. For example, if a side effect happens in 1 in 100,000 people, and a trial only studies 50,000, it may not appear at all.

After a drug is approved:
Once a medicine is prescribed to thousands or millions of people, those rare side effects start to appear. For example, in the first million patients, perhaps 10 cases may be reported. That’s not manipulation — it’s just the maths of large numbers.

How Do Doctors Link a Side Effect to a Medicine?

When someone develops a new symptom, it isn’t always obvious whether it’s caused by their illness, another condition, or the medicine they’re taking. Linking a side effect to a drug usually involves several steps:

  1. Timing – Did the symptom start soon after beginning the medicine? Did it improve when the medicine was stopped? Timing is often the strongest clue.

  2. Known side effect profile – Doctors check if the symptom has been reported before in trials, studies, or drug safety updates.

  3. Other explanations – Could it be the underlying condition (like aspergillosis) or another drug? All possible causes are reviewed.

  4. Drug interactions – Many side effects come from the way medicines interact, rather than one drug alone. Antifungals like itraconazole and voriconazole interact with steroids, antibiotics, and heart drugs.

  5. Rechallenge (rarely used) – Sometimes a drug is restarted to see if the side effect returns. This can provide strong evidence but is only done when absolutely necessary.

  6. Patient reporting – A single case may not prove much, but when dozens of patients report the same issue, patterns become clear.

🔎 Key message: It’s not always quick or simple to prove a side effect. That’s why your own observations — when it started, how it feels, what other medicines you’re on — are so valuable to your doctors and to the Yellow Card system.

What Happens to Those Patients?

  • Every case is recorded and investigated. Regulators like the MHRA (Medicines and Healthcare products Regulatory Agency) look for patterns.

  • If a link is confirmed, they can issue warnings, add monitoring requirements, restrict use, or withdraw the drug.

  • For the patients affected, the drug is usually stopped, and supportive treatment is given. Sadly, in some cases, harm cannot be reversed.

This is why reporting side effects is so important. Each individual case helps build the full safety picture and protects others in the future.

Is This “Experimenting on Patients”?

It can sometimes feel that way — because new medicines are still watched closely after approval, and some harms are only seen later.

But there’s an important distinction:

  • Clinical trials are the experiments, and they are about safety as much as efficacy. Every trial phase collects safety data, and a medicine cannot be approved unless it is shown to be safe enough for use.

  • Post-marketing monitoring is not an experiment — it’s a safety net that exists for all medicines, because no trial is ever large enough to catch every very rare problem.

Patients aren’t being experimented on after approval, but your experience does matter. Every report adds to knowledge and helps keep medicines safe for everyone.

Who Is Liable If Harm Occurs?

  • Negligence (e.g. wrong dose, ignoring abnormal tests): the prescriber or hospital may be liable.

  • Defective product or hidden data: the manufacturer may be held responsible, sometimes through compensation schemes or legal action.

  • Very rare, unpredictable events despite correct use: liability is often less clear, and compensation is not guaranteed.

This can feel unfair. A few patients may suffer harm without anyone being “at fault.” That’s why strong safety monitoring and reporting are so essential.

Balancing Benefit and Risk

If 10 people out of a million are harmed, 999,990 people may have been helped — often in life-saving ways. That doesn’t make the harm any less real, but it explains why regulators still approve medicines with very rare risks: the benefit to the vast majority outweighs the small chance of harm, as long as those harms are recognised and acted on quickly.

Looking forward, science may allow us to predict who is at risk of those 1-in-a-million harms (through genetics or biomarkers) and screen them out — so that only those who can benefit safely receive the drug.

Key UK Drug Safety Resources

Here are the most useful resources for patients in the UK:

What Aspergillosis Patients Need to Remember

Because aspergillosis often requires long-term, powerful medicines like itraconazole, voriconazole, posaconazole, steroids, or biologics, patients are more likely to:

  • Experience side effects

  • Need regular blood tests to check drug levels

  • Take multiple medicines with possible interactions

Three key takeaways:

  1. Know where to look – check NHS Medicines A–Z or your medicine leaflet (eMC) if you’re unsure about a side effect.

  2. Report problems – use the Yellow Card scheme to flag any suspected reaction.

  3. Stay in touch with your team – never stop or change your medicine without advice, but do share new symptoms with your GP or specialist promptly.

✅ Bottom line: Clinical trials test both safety and effectiveness, but no study can capture every rare event. That’s why medicines continue to be monitored after approval, and why patient reporting is so important. By working together — patients, doctors, and regulators — we make medicines safer for everyone.

by GAtherton

Side Effects, New Medicines, and Safety Reporting: What Every Patient Should Know

Modern medicines, including antifungals used for aspergillosis, can be life-saving. But they can also have powerful side effects. One patient recently described developing nerve damage (neuropathy) while on treatment, but never mentioned it to their doctor, because they didn’t know it could be a side effect. Sadly, by the time it was recognised, the damage was permanent.

This story shows why patients and doctors need to work together in partnership to spot and report side effects early — especially when medicines are new and real-world safety data is still limited.

1. From passive role to partnership

In the past, healthcare was one-way: the doctor gave instructions, the patient followed. Today the NHS encourages shared responsibility:

  • Doctors bring their expertise about the illness and treatments.

  • Patients bring their daily experience of living with the condition.

  • Together they can make safer, better-informed decisions.

This partnership is essential for powerful drugs like antifungals, where side effect monitoring depends on both sides working together.

2. Why side effect statistics can be misleading

Leaflets list side effects as “common” or “rare,” often with percentages. But these figures don’t always reflect real life because:

  • Trials are limited – only a few thousand people take part, often younger and healthier than typical NHS patients.

  • Under-reporting is common – doctors and patients often fail to report side effects, especially mild ones.

  • Bias exists – severe or unusual reactions are reported more often than everyday ones.

👉 Bottom line: leaflets tell us what can happen, not always how often it happens.

3. The Yellow Card system

The UK’s main tool for detecting safety issues is the Yellow Card Scheme, run by the MHRA.

  • Anyone can report: doctors, nurses, pharmacists, patients, or carers.

  • Reports are vital: patterns in these reports may reveal risks not seen in trials.

  • Action is taken: if needed, leaflets are updated, warnings issued, or drugs restricted/withdrawn.

You can report suspected side effects at yellowcard.mhra.gov.uk.

4. Why reporting matters

Poor reporting leads to harm:

  • Delayed warnings – e.g. photosensitivity with voriconazole took years to be recognised.

  • Biased safety data – drugs may seem safer than they are.

  • Preventable harm – patients may suffer permanent injury before action is taken.

For new medicines (marked with a ▼ black triangle in the BNF and leaflets), the MHRA asks for all side effects to be reported, no matter how small.

5. Extra protections for new medicines

When a drug is new, safety systems are stronger than usual:

  • Black triangle (▼) – signals “additional monitoring” so all suspected ADRs should be reported.

  • Specialist prescribing – new antifungals are usually limited to centres like NAC.

  • Closer monitoring – frequent blood tests, drug levels, eye or skin checks depending on risk.

  • Risk Management Plans – agreed with regulators, spelling out what to watch for.

  • Post-marketing studies – Phase 4 trials track safety in real-world patients.

These safeguards are extensive, but not fool-proof. Rare or long-term effects may still emerge only after years of wider use.

6. The NHS challenge

Despite the systems:

  • Only a small percentage of doctors file Yellow Card reports each year.

  • Most GPs never prescribe brand-new drugs — so reporting falls heavily on specialist centres like NAC.

  • Under-reporting risks harm, increases NHS costs, and erodes trust.

7. Who sets the rules?

Several organisations provide guidance on reporting and safety:

  • MHRA (UK regulator): runs Yellow Card, monitors new and established drugs, and issues safety updates.

  • BNF (British National Formulary): highlights side effects, black triangle drugs, and links to reporting tools.

  • GMC (General Medical Council): obliges doctors to report serious ADRs and all reactions to ▼ drugs.

  • EMA (European Medicines Agency): operates EudraVigilance, pooling reports from across Europe.

  • Global standards: the UK follows international rules (ICH E2B) so data is shared worldwide.

8. What patients can do

You are central to this safety net:

  • Be observant – notice anything new or unusual.

  • Keep a record – note when it started, how often, and any changes with medication.

  • Report promptly – tell your team and consider submitting a Yellow Card yourself.

  • Ask questions – “What side effects should I look out for? Which are urgent? How will we monitor this drug?”

  • Use trusted sources – NHS.uk, bnf.nice.org.uk, NAC, or your pharmacist.

9. The reality of side effects

For many, side effects are not “minor inconveniences.” They can mean:

  • Permanent disability (e.g. nerve or vision damage).

  • Loss of independence or mobility.

  • Social isolation and depression.

That’s why side effect monitoring is not just bureaucracy — it’s about protecting real lives.

Key message

The systems around new medicines are extensive but not fool-proof. That’s why patients and doctors must work as partners.

👉 If you notice something new, strange, or worrying while on antifungal medication — however small — tell your healthcare team and consider reporting it. Your report may be the missing piece that protects you and others.

by GAtherton